Omeros Corporation - OMER
About Gravity Analytica
Recent News
- 02.20.2025 - Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
- 02.20.2025 - Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
- 02.14.2025 - Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
- 02.14.2025 - Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
- 02.10.2025 - Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
- 02.10.2025 - Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
- 01.16.2025 - Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
- 01.16.2025 - Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
- 12.19.2024 - Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
- 12.19.2024 - Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA